» Articles » PMID: 16426973

SMM-chemokines: a Class of Unnatural Synthetic Molecules As Chemical Probes of Chemokine Receptor Biology and Leads for Therapeutic Development

Overview
Journal Chem Biol
Publisher Elsevier
Date 2006 Jan 24
PMID 16426973
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Chemokines and their receptors play important roles in numerous physiological and pathological processes. To develop natural chemokines into receptor probes and inhibitors of pathological processes, the lack of chemokine-receptor selectivity must be overcome. Here, we apply chemical synthesis and the concept of modular modifications to generate unnatural synthetically and modularly modified (SMM)-chemokines that have high receptor selectivity and affinity, and reduced toxicity. A proof of the concept was shown by transforming the nonselective viral macrophage inflammatory protein-II into new analogs with enhanced selectivity and potency for CXCR4 or CCR5, two principal coreceptors for human immunodeficiency virus (HIV)-1 entry. These new analogs provided insights into receptor binding and signaling mechanisms and acted as potent HIV-1 inhibitors. These results support the concept of SMM-chemokines for studying and controlling the function of other chemokine receptors.

Citing Articles

Selective Allosteric Modulation of N-Terminally Cleaved, but Not Full Length CCL3 in CCR1.

Larsen O, Luckmann M, van der Velden W, Oliva-Santiago M, Brvar M, Ulven T ACS Pharmacol Transl Sci. 2020; 2(6):429-441.

PMID: 32259075 PMC: 7088985. DOI: 10.1021/acsptsci.9b00059.


Discoveries and developments of CXCR4-targeted HIV-1 entry inhibitors.

Zhang C, Zhu R, Cao Q, Yang X, Huang Z, An J Exp Biol Med (Maywood). 2020; 245(5):477-485.

PMID: 32019336 PMC: 7082890. DOI: 10.1177/1535370220901498.


High affinity CXCR4 inhibitors generated by linking low affinity peptides.

Zhang C, Huang L, Zhu R, Meng Q, Zhu S, Xu Y Eur J Med Chem. 2019; 172:174-185.

PMID: 30978562 PMC: 6677133. DOI: 10.1016/j.ejmech.2019.03.056.


Design and evaluation of a CXCR4 targeting peptide 4DV3 as an HIV entry inhibitor and a ligand for targeted drug delivery.

Lee I, Palombo M, Zhang X, Szekely Z, Sinko P Eur J Pharm Biopharm. 2018; 138:11-22.

PMID: 29894816 PMC: 6286870. DOI: 10.1016/j.ejpb.2018.06.004.


The role of the chemokine receptor XCR1 in breast cancer cells.

Yang X, Qi L, Lin F, Ou Z Breast Cancer (Dove Med Press). 2017; 9:227-236.

PMID: 28408852 PMC: 5384703. DOI: 10.2147/BCTT.S126184.